한글목차

세계 비뇨기 로봇 기기 시장 규모는 2024년에 67억 2,000만 달러에 달했습니다. 2033년에는 285억 7,000만 달러에 달할 것으로 예상되며, 예측 기간인 2025-2033년 17.7%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

비뇨기 로봇 기기는 방광, 신장, 전립선 및 기타 관련 기관을 포함한 비뇨기 계통에 대한 최소 침습적 시술을 수행할 때 외과의사를 지원하는 데 사용되는 첨단 수술 도구입니다. 이러한 장비는 일반적으로 특수 기구가 장착된 로봇 팔, 가시성을 향상시키는 고해상도 3D 카메라, 그리고 외과의사가 시스템을 정확하게 제어할 수 있는 콘솔로 구성됩니다.

이 장비들은 절개창 축소, 회복시간 단축, 출혈량 감소, 흉터 최소화 등을 통해 섬세한 비뇨기과 수술에서 높은 정확도를 유지하면서 환자 결과를 개선할 수 있습니다.

기술의 발전은 비뇨기과 수술의 정확성, 효율성 및 결과를 향상시킴으로써 비뇨기과 로봇 기기 시장을 크게 견인하고 있습니다. 향상된 시각화, 최소침습 기술, 실시간 데이터 분석을 제공하는 강화된 로봇 시스템과 같은 기술 혁신은 외과 의사가 더 높은 정밀도와 제어력으로 복잡한 시술을 수행할 수 있도록 돕습니다. 이러한 발전은 환자의 회복 시간을 단축하고 합병증을 최소화하며 전반적인 수술 결과를 개선하기 때문에 로봇 기기는 비뇨기과에서 점점 더 인기 있는 선택이 되고 있습니다. 예를 들어, 2024년 9월에는 비뇨기과 로봇 기기 시장의 획기적인 발전이 발표되었습니다. 로봇 에너지 기반 치료 분야의 세계 리더인 EDAP TMS SA와 AI 헬스케어 선도기업인 아벤다 헬스(Avenda Health)가 전립선암 치료에 혁명을 일으키기 위한 파트너십을 체결한 것. 아벤다의 혁신적인 AI 기술인 Unfold AI를 EDAP TMS의 최첨단 로봇 고강도 집속형 초음파(HIFU) 시스템인 Focal One과 통합하여 양사는 세계 최초의 AI 지원 로봇 HIFU 시술을 시작할 예정입니다.

또한, 이러한 장비에 인공지능과 머신러닝을 통합하여 개인 맞춤형 치료 계획을 가능하게 함으로써 비뇨기과 치료에서 로봇 기술의 채택을 더욱 촉진할 수 있습니다. 그 결과, 비뇨기과용 로봇 기기에 대한 수요가 빠르게 증가하고 있으며, 이는 시장 확대와 기술 혁신으로 이어지고 있습니다.

의료기기, 특히 로봇 시스템의 승인 절차는 복잡하고 시간이 오래 걸리며, 많은 경우 대규모 임상시험, 안전성 평가, 지역 및 국제 표준에 대한 준수가 요구됩니다. 따라서 제품 출시 지연 및 개발 비용 증가로 이어질 수 있습니다. 결과적으로 이러한 규제는 시장 확대를 지연시키고 비뇨기과에서 새로운 첨단 로봇 기술의 가용성을 전반적으로 감소시킬 수 있습니다.

세계의 비뇨기 로봇 기기 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별/시술별/최종사용자별/지역별 동향, 경쟁 구도, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 조사 방법과 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 업계 분석

• 시장 리더와 선구자
• CXO의 견해
• 최신 개발과 Break through
• 사례 연구/진행중인 조사
• 규제와 상환 상황
• Porter의 Five Forces 분석
• 공급망 분석
• 특허 분석
• SWOT 분석
• 미충족 요구와 갭
• 시장 진입 및 확장을 위한 추천 전략
• 시나리오 분석 베스트 케이스, 베이스 케이스, 워스트 케이스 예측
• 가격 분석과 가격 동향
• 주요 업계 리더

제6장 제품 유형별

• 로봇 수술 시스템
• 기기와 액세서리
• 기타

제7장 시술별

• 로봇 전립선 절제술
• 로봇 방광 절제술
• 로봇 신우 성형술
• 로봇 신적출술

제8장 최종사용자별

• 병원
• 전문 클리닉
• 기타

제9장 지역별

• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타
• 라틴아메리카
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타
• 중동 및 아프리카

제10장 경쟁 구도

제11장 기업 개요

• Intuitive Surgical
• Asensus Surgical US, Inc.
• MicroPort Scientific Corporation
• Titan Medical Inc.
• Ethicon, Inc.
• Medtronic
• CMR Surgical Ltd

제12장 부록

영문목차

The global urology robotics devices market reached US$ 6.72 billion in 2024 and is expected to reach US$ 28.57 billion by 2033, growing at a CAGR of 17.7% during the forecast period 2025-2033.

Urology robotic devices are advanced surgical tools used to assist surgeons in performing minimally invasive procedures on the urinary system, including the bladder, kidneys, prostate, and other related organs. These devices typically consist of robotic arms equipped with specialized instruments, a high-definition 3D camera for enhanced visualization, and a console where the surgeon can control the system with precision.

These devices allow for smaller incisions, faster recovery times, reduced blood loss, and minimal scarring, improving patient outcomes while maintaining high levels of precision in delicate urological surgeries.

Market Dynamics: Drivers & Restraints

Technological Advancements

Technological advancements are significantly driving the urology robotic devices market by improving the precision, efficiency, and outcomes of urological procedures. With innovations like enhanced robotic systems offering better visualization, minimally invasive techniques, and real-time data analytics, surgeons can perform complex procedures with greater accuracy and control. These advancements reduce patient recovery times, minimize complications, and improve overall surgical outcomes, making robotic devices an increasingly popular choice in urology. For instance, in September 2024, A groundbreaking advancement in the urology robotic devices market was announced as EDAP TMS SA, a global leader in robotic energy-based therapies, and Avenda Health, a leading AI healthcare company, have entered into a collaboration agreement to revolutionize prostate cancer care. By integrating Avenda's innovative AI technology, Unfold AI, with EDAP TMS's cutting-edge Focal One robotic high-intensity focused ultrasound (HIFU) system, the companies are set to launch the world's first AI-assisted robotic HIFU procedures.

Additionally, the integration of artificial intelligence and machine learning in these devices allows for personalized treatment plans, further boosting the adoption of robotic technologies in urological care. As a result, the demand for urology robotic devices is rapidly growing, leading to market expansion and technological breakthroughs.

Stringent Regulatory Frameworks

The approval process for medical devices, especially robotic systems, is complex and time-consuming, often requiring extensive clinical trials, safety evaluations, and compliance with regional and international standards. This can lead to delays in product launches and increased development costs. As a result, these regulations can slow market expansion and reduce the overall availability of new, cutting-edge robotic technologies in urology.

Segment Analysis

The global urology robotics devices market is segmented based on the product type, procedure, end-user and region.

Robotic surgery systems segment in the product type is expected to dominate the urology robotics devices market

The robotic surgery systems segment is dominating the urology robotic devices market due to several key factors. Robotic surgery systems offer significant advantages in precision, control, and minimally invasive procedures, which are crucial for complex urological surgeries. These systems allow for enhanced visualization, reduced risk of human error, and quicker recovery times for patients, making them highly attractive to healthcare providers.

As the technology continues to evolve, robotic surgery systems are becoming more sophisticated, offering better outcomes and driving higher adoption rates across hospitals and surgical centers. For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded indication to treat both adult and pediatric urology patients with the Senhance Surgical System. This expansion highlights the growing dominance of the robotic surgery systems segment, as the Senhance system's advanced technology enables more precise, minimally invasive procedures in urology. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to dominate the urology robotics devices market

North America is dominating the urology robotic devices market due to several key factors. The region has a strong healthcare infrastructure with advanced medical facilities and a high adoption rate of cutting-edge technologies, including robotic surgery systems. Hospitals and surgical centers in North America are more likely to invest in expensive robotic systems due to their ability to improve patient outcomes, reduce recovery times, and minimize surgical complications.

Furthermore, North America has a well-established reimbursement structure for robotic surgeries, making it financially feasible for healthcare providers to adopt these technologies. Companies are receiving FDA approvals for their advanced innovations which are driving the region's market growth.

For instance, in July 2024, Asensus Surgical, Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indication of its Senhance Surgical System to treat both adult and pediatric urology patients. This approval reflects the region's continuous innovation and adoption of advanced medical technologies, positioning North America at the forefront of robotic-assisted surgery. North America remains a global leader in transforming healthcare through robotics, setting new standards for precision, efficiency, and patient outcomes in urological care. The region also benefits from a large, aging population with an increasing demand for urological procedures, further fueling the growth of robotic devices.

Competitive Landscape

The global market players in the urology robotics devices market are Intuitive Surgical, Asensus Surgical US, Inc., MicroPort Scientific Corporation, Titan Medical Inc., Ethicon, Inc., Medtronic and CMR Surgical Ltd., among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global urology robotics devices market report would provide approximately 45 tables, 46 figures, and 180 pages.

Target Audience 2024

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Procedure
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in Technology
    • 4.1.1.2. Increasing Prevalence of Urological Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Stringent Regulatory Frameworks
    • 4.1.2.2. Limited Availability of Trained Professionals
  • 4.1.3. Opportunities
    • 4.1.3.1. Strategic Partnerships and Collaborations
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Market Leaders and Pioneers
  • 5.1.1. Emerging Pioneers and Prominent Players
  • 5.1.2. Established leaders with largest selling Brand
  • 5.1.3. Market leaders with established Product
• 5.2. CXO Perspectives
• 5.3. Latest Developments and Breakthroughs
• 5.4. Case Studies/Ongoing Research
• 5.5. Regulatory and Reimbursement Landscape
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa
• 5.6. Porter's Five Force Analysis
• 5.7. Supply Chain Analysis
• 5.8. Patent Analysis
• 5.9. SWOT Analysis
• 5.10. Unmet Needs and Gaps
• 5.11. Recommended Strategies for Market Entry and Expansion
• 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 5.13. Pricing Analysis and Price Dynamics
• 5.14. Key Opinion Leaders

6. By Product Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 6.1.2. Market Attractiveness Index, By Product Type
• 6.2. Robotic Surgery Systems*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Instruments and Accessories
• 6.4. Others

7. By Procedure

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Robotic Prostatectomy*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Robotic Cystectomy
• 7.4. Robotic Pyeloplasty
• 7.5. Robotic Nephrectomy

8. By End-User

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Hospitals*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Specialty Clinics
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. Latin America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Mexico
    • 9.4.6.2. Brazil
    • 9.4.6.3. Argentina
    • 9.4.6.4. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Intuitive Surgical*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Asensus Surgical US, Inc.
• 11.3. MicroPort Scientific Corporation
• 11.4. Titan Medical Inc.
• 11.5. Ethicon, Inc.
• 11.6. Medtronic
• 11.7. CMR Surgical Ltd

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us